Compare ACRS & PMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACRS | PMI |
|---|---|---|
| Founded | 2012 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.8M | 202.7M |
| IPO Year | 2015 | 2025 |
| Metric | ACRS | PMI |
|---|---|---|
| Price | $3.06 | $2.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $9.75 | N/A |
| AVG Volume (30 Days) | 1.2M | ★ 2.5M |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,742,000.00 | $4,767,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.06 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 8.81 |
| 52 Week Low | $1.05 | $1.90 |
| 52 Week High | $3.48 | $13.68 |
| Indicator | ACRS | PMI |
|---|---|---|
| Relative Strength Index (RSI) | 56.89 | N/A |
| Support Level | $3.12 | N/A |
| Resistance Level | $3.48 | N/A |
| Average True Range (ATR) | 0.22 | 0.00 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 52.54 | 0.00 |
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing an implantable Total Artificial Heart. It is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including TAH. The TAH is an implantable system designed to assume the full function of a failed human heart in patients suffering from advanced heart failure.